Suplatast tosilate is an inhibitor of cytokine T helper cells. Overstimulation of these Tₕ2 cells can lead to an allergic reaction, so the drug is used as an antihistamine. It has also been used in the treatment of Kimura's disease. Chemically the active moiety is suplatast, supplied as the p-toluenesulfonate salt to improve solid state stability and handling. The compound acts by suppressing Tₕ2-type cytokine production including interleukin 4 and interleukin 5, thereby reducing IgE class switching and eosinophil recruitment; this gives a steroid-sparing effect in allergic inflammation. Typical technical characteristics include a crystalline powder form, low aqueous solubility that is increased in acidic media, stability across a pH range used for oral formulations, and compatibility with common excipients for tablets and capsules. Analytical controls are performed by HPLC for assay and related substances, by Karl Fischer for water content, and by validated GC or headspace GC methods for residual solvents. Quality control also monitors counterion content and particle size distribution to ensure consistent dissolution and bioavailability in oral dosage forms.
Parent: Suplatast Tosilate
Typical impurity and related compound limits used for batch release and specification setting are: total impurities not more than 1.0 percent area by HPLC, any individual unspecified impurity not more than 0.2 percent area by HPLC, known related compound suplatast N-oxide not more than 0.20 percent, desethyl-suplatast related impurity not more than 0.20 percent, dealkylated suplatast impurity not more than 0.05 percent, and p-toluenesulfonic acid counterion related material not more than 0.50 percent expressed on a wet basis where applicable. Acceptable residual solvent limits follow ICH Q3C guidance for frequently used solvents, for example methanol up to 3000 ppm, dichloromethane up to 600 ppm, and acetonitrile up to 410 ppm. Heavy metals are controlled to meet pharmacopeial limits, typically not more than 10 ppm total heavy metals unless local pharmacopeial limits are stricter. Stability indicating methods are used to detect degradation products after accelerated and long term storage to ensure degradation products remain within specified limits.
Suplatast Tosilate is used to reduce Tₕ2-mediated allergic inflammation by inhibiting Tₕ2 cytokine production; clinically it is used as an antihistamine and as an adjunctive therapy in allergic diseases and has been employed in conditions such as Kimura’s disease to decrease eosinophilia and IgE driven pathology.
Tolbutamide is an oral sulfonylurea antidiabetic agent used to lower blood glucose in type 2 diabetes by stimulating pancreatic beta cell insulin release; it is generally reserved for patients where diet and exercise have not achieved adequate glycemic control and is less commonly used now due to newer agents with more favorable safety profiles.
